

1. This document was created to support maximum accessibility for all learners. If you would like to print a hard copy of this document, please follow the general instructions below to print multiple slides on a single page or in black and white.
2. This handout is for reference only. Non-essential images have been removed for your convenience. Any links included in the handout are current at the time of the live webinar, but are subject to change and may not be current at a later date.
3. Copyright: Images used in this course are used in compliance with copyright laws and where required, permission has been secured to use the images in this course. All use of these images outside of this course may be in violation of copyright laws and is strictly prohibited.
4. Social Workers: For additional information regarding standards and indicators for cultural competence, please review the NASW resource: [Standards and Indicators for Cultural Competence in Social Work Practice](#)
5. Need Help? Select the “Help” option in the member dashboard to access FAQs or contact us.

How to Print Handouts

- | | |
|--|---|
| <ul style="list-style-type: none">▪ On a Mac<ul style="list-style-type: none">▪ Open PDF in Preview▪ Click File▪ Click Print▪ Click dropdown menu on the right “preview”▪ Click layout▪ Choose # of pages per sheet from dropdown menu▪ Checkmark Black & White if wanted. | <ul style="list-style-type: none">▪ On a PC<ul style="list-style-type: none">▪ Open PDF▪ Click Print▪ Choose # of pages per sheet from dropdown menu▪ Choose Black and White from “Color” dropdown |
|--|---|

No part of the materials available through the continued.com site may be copied, photocopied, reproduced, translated or reduced to any electronic medium or machine-readable form, in whole or in part, without prior written consent of continued.com, LLC. Any other reproduction in any form without such written permission is prohibited. All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of continued.com, LLC. Users must not access or use for any commercial purposes any part of the site or any services or materials available through the site.





HIV/AIDS:

transmission & infection control
considerations

A.U. Bankaitis, PhD, FAAA

Clinical Audiologist & Vice President

Oaktree Products, Inc.

St. Louis, MO

Copyright/Permissions

- All images, charts, graphs, photos and other assets in this PowerPoint are owned by the presenter, or written permission has been secured to publish them on continued.com.

Disclosures

- **Presenter Disclosure:** Non-financial disclosures: A.U. Bankaitis, PhD works for a distributor that offers infection control products. Financial disclosures: A.U. Bankaitis, PhD received an honorarium for presenting this course.
- **Content Disclosure:** This learning event does not focus exclusively on any specific product or service.
- **Sponsor Disclosure:** This course is presented by continued Social Work.

Learning Outcomes

After this course, participants will be able to:

- identify at least two ways that HIV is transmitted
- differentiate HIV-infection from AIDS based on accepted disease classification systems
- list at least 3 standard precautions related to infection control



General Objectives

- Overview of HIV/AIDS
- Immune System & HIV
- Infection Control




General Objectives

- Overview of HIV/AIDS
 - Definitions
 - Historical milestones
 - Global & domestic facts
 - Transmission & prevention




HIV AIDS

- human immunodeficiency virus



- acquired immunodeficiency syndrome




Person with HIV

HIV-1



HIV-2





General Objectives

- Overview of HIV/AIDS
 - Definitions
 - Historical milestones
 - Global & domestic facts
 - Transmission & prevention

Initial Historical Milestones

MMWR June 5, 1981

5 cases Pneumocystis carinii pneumonia (PCP)

Kaposi's sarcoma

Persistent Generalized Lymphadenopathy (PGL)

Increased demand for PENTAMIDINE

Gay Related Immuno-Deficiency (GRID)

Hemophiliac involvement

Acquired Immuno-Deficiency Syndrome (AIDS) coined
(July 27, 1982)

International Committee of Viral Taxonomy names virus


Human Immunodeficiency Virus

Basic Statistics



- Worldwide
 - ~40 million living with HIV
 - ~2.3 million newly infected/year


- United States
 - ~1.2 million living with HIV
 - ~40,000 newly infected/year with 14% unaware of status



Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013

HIV.gov, 2018

Basic Statistics






General Objectives

- Overview of HIV/AIDS
 - Definitions
 - Historical milestones
 - Global & domestic facts
 - Transmission & prevention


HIV Transmission

- Mainly spread by
 - Unprotected sex
 - Sharing needles, syringes
- Less commonly by
 - Birth
 - Breast feeding
 - Blood transfusions
 - Contaminated needle
 - Bite
 - Contact between broken skin or mucous membranes with HIV-infected blood or bodily fluids




HIV Transmission



- Mainly spread by
 - Unprotected sex
 - Sharing needles, syringes



Impact on Racial and Ethnic Minorities




Who is at Risk for HIV?




- White
- African American
- Hispanic/Latino
- Asian
- Native Hawaiian
- American Indian/Alaskan

Disproportionate Burden CDC 2020



HIV Prevention

- Mainly spread by
 - Unprotected sex
 - Sharing needles, syringes
- Less commonly by
 - Birth
 - Breast Feeding
 - Blood transfusions
 - Contaminated needle
 - Bite
 - Contact between broken skin or mucous membranes with HIV-infected blood or bodily fluids




Pre-exposure prophylaxis

- Taking daily medicine to prevent HIV for people at high risk
 - Taken daily
 - Highly effective for preventing HIV
 - Sex: 99% reduced rate
 - Injection drug use: 75% reduced rate
 - 28 days
 - Effective but not 100%



Post-exposure prophylaxis


- Taking antiretroviral meds after potential exposure
 - Within 72 hours
 - 1x – 2x daily for 28 days
 - Effective but not 100%






General Objectives

- Overview of HIV/AIDS
- Immune System & HIV
 - How it works
 - How HIV attacks immune system
 - Disease classification
 - Disease Course
 - Tests to diagnose HIV
 - Antiretroviral drug treatment
- Infection Control




PROTECT
BODY
FROM
INFECTION




IMMUNE CELL ASSEMBLY

- Bone Marrow
- Thymus
- Lymph Nodes
- Spleen, tonsils, adenoids, appendix, peyer's patches





LYMPHATIC SYSTEM






LYMPHATIC SYSTEM

- Network of vessels
- Channels lymph fluid to lymph nodes
- Directs lymph fluid toward chest
- Empties into bloodstream
- Reabsorbed by body tissues





Execute & manage all activities of the adaptive immune system




B-Cell


Lymphocytes

- Maturation process occurs within bone marrow
- Identify antigen
- Triggered to produce antigen-specific antibody proteins

ANTIGEN



Humoral Immunity




Bodily fluid = HUMOR

T-Cell


Lymphocytes


- Maturation process initiated within bone marrow
- Completed in thymus
- Several categories
- Detects antigen
- Destroys antigen


CD-4
T-Cell



Cell-Mediated Immunity










General Objectives

- Immune System & HIV
 - How it works
 - How HIV attacks immune system
 - Disease classification
 - Disease Course
 - Tests to diagnose HIV
 - Antiretroviral drug treatment

Opportunistic Infections



- Common place microorganisms
- Occur more often
- More severe degrees

Direct


touch
bodily fluid
with bare
hand

Indirect



reuse
contamina
ted
object

Droplet

cough,
sneeze in
close
proximity




HOW TO CONTROL FOR DISEASE TRANSMISSION



HOW TO CONTROL FOR DISEASE TRANSMISSION

MODE



ROUTE





General Objectives

- Immune System & HIV
 - How it works
 - How HIV attacks immune system
 - Disease classification
 - Disease Course
 - Tests to diagnose HIV
 - Antiretroviral drug treatment

Classification System-HIV/AIDS

6 years – Adult

CD4 CELL
COUNTS
CATEGORY

CLINICAL
CATEGORY **A**
(asymptomatic)


CLINICAL
CATEGORY **B**
(not A or B category)

CLINICAL
CATEGORY **C**
(AIDS indicator
condition)

1	<u>CATEGORY B:</u>
$\geq 500/(\text{mm}^3)$	Candidiasis (oropharyngeal; thrush)
2	Fever (38.5°C)
$200-499/(\text{mm}^3)$	Diarrhea >1 month
3	Herpes zoster (shingles)
$<200/(\text{mm}^3)$	etc.

Classification System-HIV/AIDS

6 years - Adult



Classification System-HIV/AIDS

Children

- Maternal HIV antibodies cross placenta
- Falsely HIV+ 9 to 18 months
- CD4+ t-cell count higher in infants

Immune
category

<12 **mths**

1-5 yrs

≥**6 yrs**

1

>1500_{μL}

>1000_{μL}

>500_{μL}

2

750-1499_{μL}

500-999_{μL}

200-499_{μL}

3

<750_{μL}

<500_{μL}

<200_{μL}

N = NO SIGNS/SYMPTOMS

A = MILD

B = MODERATE

C = SEVERE

Classification System-HIV/AIDS

Children

Absolute CD4+ T-cell Category



Clinical
Category

	N	A	B	C
1	N1	A1	B1	C1
2	N2	A2	B2	C2
3	N3	A3	B3	C3




General Objectives

- Immune System & HIV
 - How it works
 - How HIV attacks immune system
 - Disease classification
 - Disease Course
 - Tests to diagnose HIV
 - Antiretroviral drug treatment

Course of Disease

- Initially, flu-like symptoms
- Incubation period 10 or more years
- Associated with peripheral & central nervous system symptoms that manifest as communication disorders



Stages of HIV infection

acute

chronic

AIDS

- Earliest stage
- 2-4 weeks post infection
- Flu-like symptoms (fever, headache, rash)
- HIV multiplies rapidly
- High levels in blood
- Increased risk of transmission

Stages of HIV infection

acute

chronic

- Asymptomatic HIV infection
- HIV continues to multiply
- Without ART
 - ~10 years
- With ART
 - several decades
 - Essentially no risk of transmission


Stages of HIV infection

chronic

AIDS

- Final stage
- Can't fight off IO
- CD4 count < 200 cells/mm³
- Developed certain OI
- High viral load
- Able to transmit very easily
- Without ART, ~3 years

HIV/AIDS & Related Disorders



DIRECT

- Damages cell tissue
- Releases toxins
- Δ cell metabolism



INDIRECT

- Opportunistic infections
- Ototoxicity

INDIR
ECT

Opportunistic infections

- Herpes simplex virus (HSV-1)
 - Sores on lips and mouth
- *Salmonella*
 - Bacterial infection affecting intestines
- Candidiasis (thrush)
 - Fungal infection of mouth, trachea, lungs
- Toxoplasmosis
 - Parasitic infection that affects the brain



Opportunistic infections

- **Complete list:**

<https://www.cdc.gov/hiv/basics/livingwithhiv/opportunisticinfections.html>

- **Pneumonia**
- **Cancer**
- **Infections of the brain**
- **Diarrheal disease**

INDIR
ECT

Ototoxicity

- FDA-approved and/or experimental anti-retrovirals
- Medications for opportunistic infections
- SNHL, tinnitus, vestibular/balance issues



Hearing Loss Comorbidities

~15% of Adults in US (37.5 million) report trouble hearing






General Objectives

- Immune System & HIV
 - How it works
 - How HIV attacks immune system
 - Disease classification
 - Disease Course
 - Tests to diagnose HIV
 - Antiretroviral drug treatment

HIV Tests

TYPES:



- Antibody test




- Antigen/Antibody



- Nucleic Acid (RNA)




What HIV Results Mean

- Negative Test Result 
 - Seroconversion takes 2 weeks – 6 months
 - Retest in 3 months
- Positive Test Result 
 - Confirmatory test (Western Blot test)
 - Postexposure Prophylaxis Regimen

HIV Testing – Legal Issues

- For patients in all health-care settings
 - Routine voluntary HIV screening after patient notified testing will be performed unless patient declines (*opt-out screening*)
 - Separate written consent not required
 - Persons at high risk screened at least annually
 - Prevention counseling should not be required with HIV diagnostic testing or as part of screening



CDC (2006)

Current vs Previous Recommendations

SAME

- HIV testing voluntary
- Recommended/routine for those seeking STD treatment
- Access to care, counseling, & support services essential



DIFFERENT

- Screen after notification unless patient opts-out
- NO specific consent
- Annual screening for persons at high risk
- HIV results provided in same manner as all tests
- Prevention counseling not required for screening programs
- Screening/Diagnostics distinct from counseling

For pregnant women

- Routine panel of prenatal screening tests
- Voluntary HIV screening after patient notified testing will be performed unless patient declines (opt-out screening)
- Separate written consent not required
- Repeat screening in 3rd trimester recommended in certain jurisdictions with elevated HIV rates amongst pregnant women





General Objectives

- Immune System & HIV
 - How it works
 - How HIV attacks immune system
 - Disease classification
 - Disease Course
 - Tests to diagnose HIV
 - Antiretroviral drug treatment

Antiretroviral Drugs for treatment of HIV & AIDS

- HIV = RETROVIRUS



Antiretroviral Drugs for treatment of HIV & AIDS

- Integrase Inhibitors
 - Stop action of enzyme HIV uses to infect cell
- Reverse transcriptase inhibitors
 - Interrupt HIV life-cycle as it tries to copy itself





General Objectives


- Infection control
 - Standard Precautions
 - Key COVID-19 precautions
 - Practical application in work environments



HICPAC
HEALTHCARE INFECTION CONTROL
PRACTICES ADVISORY COMMITTEE



HIV/AIDS



BODY
SUBST
ANCE
ISOLAT
ION



UNIVERSA
L
PRECAUTI
ONS



STANDARD
PRECAUTIONS

CDC's Response to HIV/AIDS

1983

- CDC Guideline for Isolation Precautions in Hospitals

1985

- CDC expanded blood & bodily fluid precautions to prevent HIV transmission

1987

- All blood treated as if infected with HIV


1996

UNIVERSAL
PRECAUTIONS

BODY
SUBST
ANCE
ISOLAT
ION

STANDARD
PRECAUTIONS

Standard Precautions



- Personal Protective Equipment
- Hand hygiene
- Cleaning and Disinfecting
- Waste Removal
- Safe infection practice
- Cough Etiquette

Infection Control

‘....conscious management of the clinical environment for purposes of minimizing or eliminating the potential spread of disease’

Bankaitis & Kemp, 2003, 2004




General Objectives

- Infection control
 - Standard Precautions
 - Key COVID-19 precautions
 - Practical application in work environments

SPREAD

SARS-CoV-2

CORONAVIRUS DISEASE COVID-19



6 feet

RESPIRATORY DROPLETS




TOUCH SURFACES
FOLLOWED BY FACE

SPREAD

SARS-CoV-2

CORONAVIRUS DISEASE COVID-19



6 feet

RESPIRATORY DROPLETS

HIA




TOUCH SURFACES
FOLLOWED BY FACE

COVID-19 & HIV

- ~50% HIV+ in US
≥ 50 years of age
- Effective treatment
= equal risk





PERSONAL BARRIERS

Masks

Audiologists, staff, students & patients to wear a mask



Medical Mask



Aerosol-generating
procedure

N95 Mask

HAND HYGIENE

Hand Sanitizers

60% ethanol

70% isopropanol



HAND HYGIENE

When

- Often
- Patient appointment
- Before
- During as needed (including glove removal)
- After
- After coughing/sneezing, blowing nose
- Before eating
- Before touching face

DISINFECT

DEFINITION

Kill germs

EPA-Registered
Hospital Grade

QUALIFIED DISINFECTANTS FOR COVID-19

The U.S. Environmental Protection Agency (EPA) released an expanded list of EPA-registered disinfectant products qualified for use against COVID-19. While these products have not been specifically tested against COVID-19, they are expected to be effective because these products have been tested and proven effective on either a harder-to-kill virus or against another similar human coronavirus.¹

The products listed below represent disinfectant products from the EPA's expanded list offered by Oaktree Products.

Item number	Clickable Product Link	Qualification
00708	Audiologist's Choice Ultrasonic	List N (EPA Reg. No. 1839-94)
13-1100	CaviWipes (canister)	Kills SARS-CoV-2
30824	Clorox Hydrogen Peroxide (wipes)	List N (EPA Reg. No. 67619-25)
30825	Clorox Hydrogen Peroxide (wipes)	List N (EPA Reg. No. 67619-25)
30828	Clorox Hydrogen Peroxide (24 oz spray)	List N (EPA Reg. No. 67619-25)
C-24	Cavicide Disinfectant (24oz spray)	List N (EPA Reg. No. 46781-6)
C-64	Cavicide Disinfectant (1 gallon)	List N (EPA Reg. No. 46781-6)
H59200	Sani-Cloth AF3 Alcohol-Free (singles)	List N (EPA Reg. No. 9480-9)
35910	SaniZide Pro 1 (32 oz spray)	List N (EPA Reg. No. 88494-3)
HO4082	Super Sani-Cloth (singles)	List N (EPA Reg. No. 9480-4)
P13872	Sani-Cloth AF3 Alcohol-Free (canister)	List N (EPA Reg. No. 9480-9)
P25372	Sani-Cloth Prime (wipes)	List N (EPA Reg. No. 9480-12)
Q55172	Super Sani-Cloth (wipes)	List N (EPA Reg. No. 9480-4)

DISINFECT

What

- Touch surfaces
- Splash surfaces

How

- Read instructions
- Clean
- Apply
- Dwell Time



General Objectives

- Infection control
 - Standard Precautions
 - Key COVID-19 precautions
 - Practical application in work environments

Practical applications



Consider & plan for telemedicine appts



Know how to contact health department

<https://www.astho.org/Directory/>



Stay connected with health department



Assess & restock IC supplies NOW and on a regular basis

PERSONAL BARRIERS

Masks

CDC & FDA identified use of respirators approved under standards in other countries is acceptable



KN95 Mask
GB2626-2006
GB2626-2019



N95 Mask

PERSONAL BARRIERS

Masks

- Extended
 - Wear same mask with multiple patients
 - Put on and keep on
 - Once remove it, dispose
 - Tie-on, N95/KN95
- Reuse
 - Wear same mask with multiple patients
 - Put on and take off
 - Continue to reuse until need to dispose
 - Ear or head loop mask

PERSONAL BARRIERS

Masks



- Extended



- Reuse



MASKS & SPEECH UNDERSTANDING



LOW

MID

HIGH



TIPS for COMMUNICATING

- Speak slowly 
- Reduce noise 
- Hearing aids 
- Portable hearing amplifier 
- Rephrase remarks 
- Do not shout/over-emphasize 
- Take turns talking 



Personal Barriers - Face Shields

Early during the pandemic, face shields were originally deemed an appropriate alternative to traditional masks throughout spring 2020 (CDC, 2020a). By late summer 2020, the CDC updated guidance recommendations, qualifying face shields as a form of eye protection only (CDC, 2020b) although exceptions have been made. Providers who interact with individuals with hearing loss may find that a face shield helps facilitate more effective communication and wearing a hooded face shield or one that extends below the chin and wraps around both sides of the face may be considered (CDC, 2021)

References:

- Centers for Disease Control and Prevention (2020a). Strategies for optimizing the supply of facemasks. Retrieved from: www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/face-masks.html
- Centers for Disease Control and Prevention (2020b). Operational considerations for personal protective equipment in the context of supply shortages for coronavirus disease 2019 (COVID-19) pandemic: non-US healthcare settings. Retrieved from: www.cdc.gov/coronavirus/2019-ncov/hcp/non-us-settings/emergency-considerations-ppe.html
- Centers for Disease Control and Prevention (2021). Strategies for optimizing the supply of facemasks. Retrieved from: www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/face-masks.html

MASKS WITH CLEAR PANELS

ClearMask™

Disposable, anti-fog



Communicator Mask
Disposable



Smile Mask
(Reusable Cloth)

HAND HYGIENE

Hand Sanitizers

60% ethanol

70% isopropanol

Soap & Water

Plain

Anti-microbial




DISINFECT Forms





COVID-19 & HIV Patients

AVOID CLOSE CONTACT



MASK UP



- Cover mouth
- Cover nose
- Wear mask even if you do not feel sick
- Wear mask in public & around people who do not live in households
- NOT substitute for social distancing

WASH HANDS OFTEN

- Soap and water for at least 20 seconds
 - After being in public place
 - After blowing nose, coughing, sneezing
 - Before eating/food prep
 - Before touching face
 - After using restroom
 - After handling your mask
 - After changing a diaper
 - Touching mask
 - After caring for someone sick
 - After touching animals/pets



Wash Hands Often

20
Sec



- After in public place
- After blowing nose, coughing, sneezing
- Before eating/food prep
- Before touching face
- After using restroom
- After handling your mask
- After changing a diaper
- Touching mask
- After caring for someone sick
- After touching pets



Healthcare Provider Posters



[Clean Hands Count Poster](#)
[PDF 6.8 MB]



[My Clean Hands Count For My Family Poster](#)
[PDF 5.5 MB]

Materials

sheet




[Clean Hands Count Fact Sheet](#)

FREE POSTERS & BROCHURES

COVER COUGHS & SNEEZES

- Always cover mouth and nose
 - tissue
 - inside of elbow
- Immediately wash hands
 - Soap & water
 - Hand sanitizer



CLEAN & DISINFECT

- Touch surfaces
 - Tables
 - Doorknobs
 - Countertops
- EPA-registered household disinfectants



Disinfectant

SYMPTOMS OF CORONAVIRUS DISEASE 2019

Patients with COVID-19 have experienced mild to severe respiratory illness.

FEVER



Symptoms* can include

**SHORTNESS
OF BREATH**



COUGH




***Symptoms may appear 2-14
days after exposure.**




MONITOR HEALTH DAILY

IF SYMPTOMS DEVELOP

- Keep track of your symptoms
- Contact your healthcare provider
- If you have:
 - trouble breathing
 - persistent chest pain/ pressure
 - new confusion
 - bluish lips or face






Summary



HIV $\neq$ AIDS

Ethnic/Racial
disproportion



CD4
T-Cell

HIV target
OI's
Susceptible



Key
precautions

Infection
control
resources

A.U. Bankaitis, PhD, FAAA
Oaktree Products

au@oaktreeproducts.com

References

Center for Disease Control and Prevention. (2018). *Diagnoses of HIV in the United States*.
<https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-31/index.html>

Centers for Disease Control and Prevention. (2020, March 11). *Get Your Clinic Ready for COVID-19*.
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinic-preparedness.html>

Bankaitis, A.U. (2008). Infection Control. In: H. Dunn, R. Roeser and M. Valente (Ed) *Audiology: Practice Management* (2nd edition) (p. 215-226). Thieme Publishing.

Bankaitis, A.U. (2010). Infection Control. *Canadian Hearing Report*, 5(2): p. 38-43.

Bankaitis, A.U. (2010). Infection Control for Communication, Hearing and Swallowing Disorders. In: D.W. Swanepoel and B. Louw (Eds.) *HIV/AIDS: A Clinical Resource for Communication, Hearing and Swallowing Disorders* (p. 63-98). Plural Publishing.

Bankaitis, A.U. (2011). Infection Control: Getting Your Practice Compliant with OSHA Standards. *Audiology Practices*, 2(2): p. 22-27.

Bankaitis, A.U. (2018). Infection Control. In: B. Taylor (Ed). *Audiology Practice Management*, 3rd edition. Thieme Medical Publishers.

Hoover, K. W., Huang, Y.-L. A., Tanner, M. L., Weiming Zhu, Gathua, N. W., Pitasi, M. A., DiNenno, E. A., Nair, S., & Delaney, K. P. (2020). HIV Testing Trends at Visits to Physician Offices, Community Health Centers, and Emergency Departments - United States, 2009-2017. *MMWR: Morbidity & Mortality Weekly Report*, 69(25), 776–780. <https://doi.org/10.15585/mmwr.mm6925a2>

Joshua, T. G., Williams, W. O., Benton, S., & Uhl, G. (2020). Evaluation of an HIV prevention intervention for women living with HIV. *AIDS Care*, 32(7), 835–842. <https://doi.org/10.1080/09540121.2019.1659910>

UNAIDS. (2013). *Global Report*
[https://files.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS Global Report 2013 en.pdf](https://files.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf)

United States Department of Health of Human Services. (2020, June 30). *U.S. Statistics*.
<https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics#:~:text=An%20estimated%2036%2C400%20new%20HIV,distributed%20across%20states%20and%20regions>

Cultural Competence

For additional information regarding standards and indicators for cultural competence, please review the NASW resource: *Standards and Indicators for Cultural Competence in Social Work Practice*

<https://www.socialworkers.org/LinkClick.aspx?fileticket=7dVckZAYUmk=&portalid=0>

A.U. Bankaitis, PhD, FAA
Oaktree Products, Inc.

800.347.1960

www.oaktreeproducts.com

au@oaktreeproducts.com